These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 2939465)

  • 1. Comparison of motor depressant effects of caerulein and N-propylnorapomorphine in mice.
    Vasar E; Maimets M; Nurk A; Soosaar A; Allikmets L
    Pharmacol Biochem Behav; 1986 Mar; 24(3):469-78. PubMed ID: 2939465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential involvement of CCK-A and CCK-B receptors in the regulation of locomotor activity in the mouse.
    Vasar E; Harro J; Lang A; Pôld A; Soosaar A
    Psychopharmacology (Berl); 1991; 105(3):393-9. PubMed ID: 1798834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Similar behavioral and biochemical effects of long-term haloperidol and caerulein treatment in albino mice.
    Vasar E; Allikmets L; Soosaar A; Lang A
    Pharmacol Biochem Behav; 1990 Apr; 35(4):855-9. PubMed ID: 2111914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subdiaphragmatic vagotomy does not prevent the anti-exploratory effect of caerulein in the elevated plus-maze.
    Vasar E; Lang A; Harro J; Kõks S; Volke V; Sihver S; Bourin M; Bradwejn J; Männistö PT
    Neuropeptides; 1994 Jan; 26(1):39-45. PubMed ID: 8159285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in motor activity and forebrain [propionyl-3H]propionylated-CCK-8 binding in mice after repeated administration of drugs affecting cholecystokinin receptors.
    Vasar E; Stephenson JD; Meldrum BS
    Eur J Pharmacol; 1991 Sep; 202(3):385-90. PubMed ID: 1748160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anxiogenic-like action of caerulein, a CCK-8 receptor agonist, in the mouse: influence of acute and subchronic diazepam treatment.
    Harro J; Põld M; Vasar E
    Naunyn Schmiedebergs Arch Pharmacol; 1990; 341(1-2):62-7. PubMed ID: 2314484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraventricular injection of neurotensin reduces dopamine D2 agonist binding in rat forebrain and intermediate lobe of the pituitary gland. Relationship to serum hormone levels and nerve terminal coexistence.
    von Euler G; Meister B; Hökfelt T; Eneroth P; Fuxe K
    Brain Res; 1990 Oct; 531(1-2):253-62. PubMed ID: 1981163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of an imidazobenzodiazepine (RO 15-1788) on aggressive behavior in mice].
    Vasar EE; Maĭmets MO; Riago LK; Nurk AM; Allikmets LKh
    Biull Eksp Biol Med; 1984 Oct; 98(10):441-3. PubMed ID: 6208949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes at cholecystokinin receptors induced by long-term treatment with diazepam and haloperidol.
    Vasar E; Soosaar A; Harro J; Lang A
    Eur Neuropsychopharmacol; 1992 Dec; 2(4):447-54. PubMed ID: 1490096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. beta-Endorphin involvement in the antidopaminergic effect of caerulein.
    Matsubara K; Matsushita A
    Jpn J Pharmacol; 1986 Mar; 40(3):417-22. PubMed ID: 2940395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ondansetron, an antagonist of 5-HT3 receptors, antagonizes the anti-exploratory effect of caerulein, an agonist of CCK receptors, in the elevated plus-maze.
    Vasar E; Peuranen E; Oöpik T; Harro J; Männistö PT
    Psychopharmacology (Berl); 1993; 110(1-2):213-8. PubMed ID: 7870888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of N-n-propylnorapomorphine enantiomers on single unit activity of substantia nigra pars compacta and ventral tegmental area dopamine neurons.
    Cox RF; Neumeyer JL; Waszczak BL
    J Pharmacol Exp Ther; 1988 Oct; 247(1):355-62. PubMed ID: 3171980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological characterization of the receptors involved in the apomorphine-induced polyphasic modifications of locomotor activity in mice.
    Protais P; Bonnet JJ; Costentin J
    Psychopharmacology (Berl); 1983; 81(2):126-34. PubMed ID: 6138794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the dopaminergic effects of apomorphine and (-)-N-n-propylnorapomorphine.
    Menon MK; Clark WG; Neumeyer JL
    Eur J Pharmacol; 1978 Nov; 52(1):1-9. PubMed ID: 569056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Central depressant effects of caerulein and cholecystokinin octapeptide (CCK-8) differ from those of diazepam and haloperidol.
    Zetler G
    Neuropharmacology; 1981 Mar; 20(3):277-83. PubMed ID: 6267504
    [No Abstract]   [Full Text] [Related]  

  • 16. Characteristics of the dopamine receptors involved in the anorectic effects of apomorphine in mice.
    Duterte-Boucher D; Naudin B; Costentin J
    Fundam Clin Pharmacol; 1989; 3(4):337-46. PubMed ID: 2553567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroleptic-like properties of cholecystokinin analogs: distinctive mechanisms underlying similar behavioral profiles depending on the route of administration.
    De Witte P; Gewiss M; Roques B; Vanderhaeghen JJ
    Peptides; 1988; 9(4):739-43. PubMed ID: 2906429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clonidine and yohimbine separate the sedation and the ptosis caused by cholecystokinin octapeptide and ceruletide.
    Zetler G
    Eur J Pharmacol; 1984 Jul; 102(2):333-40. PubMed ID: 6090162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. L364,718 antagonizes the cholecystokinin-induced suppression of locomotor activity.
    Soar J; Hewson G; Leighton GE; Hill RG; Hughes J
    Pharmacol Biochem Behav; 1989 Jul; 33(3):637-40. PubMed ID: 2587606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential anatomical location of [3H]-N,n-propylnorapomorphine and [3H]-spiperone binding sites in the striatum and substantia nigra of the rat.
    Hall MD; Jenner P; Kelly E; Marsden CD
    Br J Pharmacol; 1983 Jun; 79(2):599-610. PubMed ID: 6418246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.